Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707248 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
A Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
- 13
- Study locations
NCT04707248: Active Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor, sponsored by Daiichi Sankyo.
NCT04707248 is a Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 179 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (26% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04707248, a Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
- 13
- Study locations
Study Summary
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.
Conditions Studied
Interventions
- DRUG DS-6000a
Study Locations (13)
Other
- National Hospital Organization Kyusyu Cancer Center - Fukuoka
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research - Kōtoku
- National Hospital Organization Shikoku Cancer Center - Matsuyama
- Shizuoka Cancer Center - Nakatogari
- Saitama Medical University International Medical Center - Saitama
Tennessee
- SCRI Oncology Partners - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Tokyo
- National Cancer Center Hospital - Chuo Ku
- National Cancer Center Hospital East - Kashiwa-shi
Arizona
- Arizona Oncology Associates, PC HOPE (A)A HOPE) - Tucson
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- Florida Cancer Lake Mary - Lake Mary
Oklahoma
- Oklahoma University - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT04707248 still lists
NCT04707248 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (26% lower).
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which DS-6000a is the first listed.
NCT04707248 lists 13 locations in 7 states (Other, Tennessee, Tokyo).
Frequently Asked Questions
What is clinical trial NCT04707248 about?
NCT04707248 is a clinical study titled "A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors". This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse...
What is the current status of trial NCT04707248?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2020-12-22. Estimated completion is 2026-06-30.
What conditions does trial NCT04707248 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Ovarian Tumor.
What interventions are being tested in trial NCT04707248?
The interventions under investigation include: DS-6000a (DRUG).
Who is sponsoring clinical trial NCT04707248?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04707248 being conducted?
This trial has 13 study locations across Arizona, Colorado, Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04707248's enrollment target sits among peer trials
179 33rd of 121 higher than 88 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI